Diabetic Dogs Needed for Study that Could Reduce or Eliminate Insulin Injections
- S&P 500, Dow climb for third day and close at records
- Tesla (TSLA) China Numbers 'Robust' - Wedbush
- Apple (AAPL) Shares Seen as 'Attractive' as Recent Checks Show Continuously Strong Demand - Citi
- Amazon.com warehouse workers vote to reject forming union in Alabama
Get inside Wall Street with StreetInsider Premium. Claim your 1-week free trial here.
BOONE, Iowa, March 19, 2021 /PRNewswire/ -- Gene therapy company ENDSULIN has expanded to a second study site at Boone Veterinary Hospital, where it is looking for diabetic dogs to participate in a study to evaluate the effectiveness of a treatment that could reduce or even eliminate insulin injections.
The study could be a critical step in advancing a one-time gene therapy treatment for diabetes in both dogs and humans. The treatment, which has proven efficacy in hundreds of small animals, is based on more than 25 years of research at the University of Wisconsin Hospitals and Clinics in Madison, where the company is based.
"We hope to free families who are caring for their diabetic pets around the clock," said Hans Sollinger, ENDSULIN founder. "Giving dogs and their families their independence back is a step in our mission to do the same for millions of people suffering with diabetes."
ENDSULIN covers the cost of the procedure, which takes about 30 minutes total and is administered by a certified veterinarian. After treatment, the ENDSULIN team will periodically monitor dogs' health to observe the long-term effects.
While this particular gene therapy is novel, dogs treated with gene therapies in Barcelona, Spain have been followed for up to 8 years, with no evidence of adverse events.
Ideal dogs are small, and have been recently diagnosed with diabetes. Families must be able to bring their pet to either the Boone or Waunakee, WI, clinics for the one-time treatment and five follow-up visits, and also provide follow-up information to the ENDSULIN research team.
ABOUT ENDSULINENDSULIN is reshaping the way we approach a cure for diabetes. They are working to free patients from daily injections and 24/7 management using the most cutting-edge gene therapy technology, developed from decades of research by noted diabetes leader Hans Sollinger, MD, PhD, Dr hc, at the University of Wisconsin Hospitals and Clinics. Their sole focus is to get a durable, one-time treatment to the millions of people who need it.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Brandon Dawson Raises $250,000 For The Grant Cardone Foundation
- Brisbane 8th Grader, Joshua Wood, Takes Home the Grand Prize in Lions Clubs International Peace Essay Contest
- Synlogic Presents Data from SYNB1891 Phase 1 Trial at American Association for Cancer Research (AACR) Annual Meeting